Targeted epigenetic therapies: the next frontier?

Journal of the National Cancer Institute

Volumn 102, Issue 24, 2010, Pages 1824-1825

  Tuma, Rabiya S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARID1A PROTEIN, HUMAN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 3A; EZH2 PROTEIN, HUMAN; NONHISTONE PROTEIN; NUCLEAR PROTEIN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; UTX PROTEIN, HUMAN;

ADENOCARCINOMA; DRUG EFFECT; FEMALE; GENE DELETION; GENETIC EPIGENESIS; GENETICS; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MUTATION; NOTE; OVARY TUMOR;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC AGENTS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; FEMALE; GENE DELETION; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 79952116389     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq520     Document Type: Note

References (0)